In August 2018, patisiran, a first-in-class therapy was approved in the US and EU to treat the polyneuropathy associated with a genetic disease 002D hereditary transthyretin-mediated amyloidosis. The therapy uses small pieces of ribonucleic acid (RNA) to effectively ‘silence’ a faulty gene, without changing the deoxy ribonucleic acid (DNA) of the patient. This is significant! The Dogma of Molecular Biology has been overturned Watson and Crick demonstrated the double-helical structure of DNA in 1953 and
Translating a discovery in biology to a marketable medical breakthrough is a long drawn, tedious, high-investment, and high-risk process. Drug repurposing / repositioning has turned into a popular strategy of late. Not quite the same as traditional drug development techniques, the strategy is productive, affordable and is associated with reduced risk compared to novel molecular entities. What is it, really? According to NCATS of the US NIH, drug repurposing generally refers to studying a drug
    The story back then… Cannabis’ (Marijuana) use as medicine dates back to 4000 BC in China. During the 19th century and till early 20th century, marijuana was used globally, to treat various illnesses such as migraine, neuropathic pain, musculoskeletal pain and in childbirth.2 In Canada, cannabis was added to the Confidential Restricted List in 1923 under the Narcotics Drug Act Amendment Bill.3 Cannabis was listed under Schedule 1 drugs and made illegal in
value-based care

Healthcare: Shift from Volume to Value

Posted by Neha Arora on  July 18, 2019
Category: Healthcare
Healthcare is an expanding and complex industry. The ageing population, higher prevalence of chronic diseases, advances in digital technologies, highly efficacious and expensive drugs have led to an increase in the healthcare demand and expenditures. The global health care spending projected at $ 10.05 Trillion by 2022 represents 2018-2022 CAGR of 5.4%, a considerable rise from 2.9% in 2013–20171 Having said that, the healthcare systems are shifting from volume-based care (fee for service) to value
It’s been almost 3 years since the British voted 52-48% to leave the EU on 23rd June 2016.12  Given the lack of clarity and ensuing uncertainty, the pharmaceutical companies have been planning for a worst-case scenario i.e. no-deal. We will look at the most important (subjectively assessed) implications of a no-deal Brexit scenario for Pharmaceutical industry. Before I discuss the potential consequences of a no-deal Brexit, here are some metrics that reflect the importance of
3D Printing
Biofabrication can be defined as the production of complex living and non-living biological products from raw materials such as living cells, molecules, extracellular matrices, and biomaterials. – Mironov et al., 2015. First things first…What´s 3D printing? The standard two-dimensional (2D) printing is the act of depositing ink on a 2D surface of a medium e.g. paper, cloth, plastic etc. This type of printing involves the horizontal and vertical directions generally known as X and Y